摘要 |
<p>Vaccine formulations and therapeutic methods therefor containing respiratory syncytial viral proteins or immunological fragment and an adjuvant selected from the group consisting of QS-21, 3-deacylated monophosphoryl lipid A, monophosphoryl lipid A and combination are described herein. Presence of the adjuvant(s) significantly increases the humoral and cell-mediated immunogenicity of the RSV proteins.</p> |